<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82340">
  <stage>Registered</stage>
  <submitdate>12/10/2007</submitdate>
  <approvaldate>5/11/2007</approvaldate>
  <actrnumber>ACTRN12607000566437</actrnumber>
  <trial_identification>
    <studytitle>Long Chain Omega-3 Polyunsaturated Fatty Acids and Heart Health in Humans</studytitle>
    <scientifictitle>A randomised dose-response trial to determine the effects of omega-3 fatty acids in treatment of mild hypertriglyceridemia in young women to reduce the risk of cardiovascular disease</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Mild hypertriglyceridaemic subjects</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is a dose-response study therefore participants will be randomized to one of 4 dose groups (0, 0.3, 0.7 or 1.0g/day) of long chain omega-3 fatty acids (Nu-Mega DHA-rich tuna oil capsules, 500mg).
Duration is 2 menstrual cycles (approximately 8 weeks).
0.3g/day group consumes 2 tuna oil capsules and 4 placebo capsules per day; the 0.7g/day group consumes 4 tuna oil capsules and 2 placebo capsules per day; and the 1.0g/day group consumes 6 tuna oil capsules per day. These 3 dose groups will be compared to 1 placebo group which consumes 6 placebo capsules per day (Sunola oil).</interventions>
    <comparator>Placebo Sunola capsules, taken for 2 menstrual cycles (approximately 8 weeks). 0g/day long chain omega-3 polyunsaturated fatty acid (LCn3PUFA) group will consume only placebo capsules (6 per day).</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Fasting plasma triglycerides (measured using an autoanalyser (Konelab, Thermo Electron) and standard assay kits.</outcome>
      <timepoint>At baseline and approximately 8 weeks after start of intervention (2 menstrual cycles)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Lipoprotein levels and particle size (VLDL, IDL, LDL and HDL). Lipoproteins will be isolated from plasma using sequential ultracentrifugation. Particle size will be determined using gradient gel electrophoresis, and composition analysis will be conducted using an autoanalyser.</outcome>
      <timepoint>At baseline and approximately 8 weeks after start of intervention (2 menstrual cycles)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Fatty acid profile of erythrocytes, plasma and whole blood from the fingertip.</outcome>
      <timepoint>At baseline and approximately 8 weeks after start of intervention (2 menstrual cycles)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Blood pressure</outcome>
      <timepoint>At baseline and approximately 8 weeks after start of intervention (2 menstrual cycles)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Glucose and insulin levels, which will be meaured using Enzyme-Linked ImmunoSorbent Assay (ELISA)</outcome>
      <timepoint>At baseline and approximately 8 weeks after start of intervention (2 menstrual cycles)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Female, generally healthy, regular menstrual cycles, plasma triglycerides &gt;1.0mmol/L at screening visit.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>40</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Pregnant, irregular menstrual cycles, anemia, or plasma triglycerides &lt; 1mmol/L at screening visit.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by computer</concealment>
    <sequence>Computer Software Microsoft Excel
Stratified Allocation based on age, body mass index (BMI) and contraceptive pill use</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>10/09/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>120</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2500</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Wollongong</primarysponsorname>
    <primarysponsoraddress>Northfields Ave, Wollongong NSW 2522</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Australian Research Council Australian Postgraduate Award-Industry (ARC APA-I)</fundingname>
      <fundingaddress>1st Floor, 8 Brindabella Circuit
Brindabella Business Park
CANBERRA AIRPORT ACT 2609
AUSTRALIA</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Nu-Mega Ingredients (now Clover Corporation)</fundingname>
      <fundingaddress>53 Fairlawn Street,
Nathan, Brisbane, QLD 4111</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Analytical Reference Laboratories</fundingname>
      <fundingaddress>Ground Floor, 568 St Kilda Rd, 
Melbourne, VIC 3004</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This project aims to determine the dose-response effect of low doses of long chain omega-3 polyunsaturated fatty acids on plasma triglyceride levels in pre-menopausal women with mildly elevated triglycerides. The dose-response effect on plasma lipoprotein levels and particle size, as well as omega-3 levels in various blood samples (plasma, erythrocytes, whole blood from fingertip) will also be investigated.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Wollongong Human Research Ethics Committee</ethicname>
      <ethicaddress>Research Services Office
Building 20, Level 1
University of Wollongong
Northfields Ave, Wollongong NSW 2522</ethicaddress>
      <ethicapprovaldate>1/02/2007</ethicapprovaldate>
      <hrec>HE06/317</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Cassandra Sparkes</name>
      <address>School of Health Sciences
University of Wollongong
Northfields Ave
Wollongong NSW 2522</address>
      <phone>02 4221 4274</phone>
      <fax>02 4221 3486</fax>
      <email>cs76@uow.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Cassandra Sparkes</name>
      <address>School of Health Sciences
University of Wollongong
Northfields Ave
Wollongong NSW 2522</address>
      <phone>02 4221 4274</phone>
      <fax>02 4221 3486</fax>
      <email>cs76@uow.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Cassandra Sparkes</name>
      <address>School of Health Sciences
University of Wollongong
Northfields Ave
Wollongong NSW 2522</address>
      <phone>02 4221 4274</phone>
      <fax>02 4221 3486</fax>
      <email>cs76@uow.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>